BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 23, 2016
View Archived Issues
Yisheng completes phase I trial of PIKA hepatitis B vaccine
Read More
Taisho Pharmaceutical's TP-0463518 in clinical development for renal anemia
Read More
CRISPR/Cas9 gene editing advances, first patient receives cells with edited genes
Read More
Oral, ultra-long-acting form of ivermectin achieves sustained therapeutic serum drug concentrations
Read More
Chiesi Farmaceutici acquires Atopix Therapeutics
Read More
Karolinska Development company raises funds to advance development of GR-3027
Read More
Eli Lilly Japan and Torii Pharmaceutical launch Taltz in Japan
Read More
BioLineRx inlicenses project for dry eye syndrome
Read More
KalVista Pharmaceuticals closes merger with Carbylan
Read More
Immunovaccine's DPX-Survivac wins EMA orphan drug designation
Read More
ENDURANCE-4 trial shows efficacy of glecaprevir/pibrentasvir in HCV genotypes 4-6
Read More
Ability Pharmaceuticals begins phase II study of ABTL-0812
Read More
FDA issues complete response letter for Green Cross's IVIG-SN
Read More
Enamine and Pcovery extend collaboration
Read More
Phase III trial of mepolizumab for eosinophilic granulomatosis with polyangiitis meets endpoints
Read More
Gates Foundation grant supports NovoBiotic's work on orally active analogues of teixobactin for TB
Read More
Cancer candidate PRI-724 shows antifibrotic potential in patients with HCV and cirrhosis
Read More
Farnesoid X receptor agonist LJN-452 well tolerated in first-in-human study
Read More
Acorda ends development of dalfampridine to improve post-stroke walking difficulties
Read More
FDA grants orphan drug designation to PQR-309
Read More
Primary endpoint not met in phase III study of solanezumab for mild dementia due to Alzheimer's
Read More
Ruga Corporation changes name to Aravive Biologics
Read More
Rgenix patents SLC6A8 inhibitors for cancer
Read More
University of Colorado patent reveals beta-lactam antibiotic sensitizers
Read More
AstraZeneca describes LTC4 synthase inhibitors
Read More
Chiesi Farmaceutici reports compounds for asthma and COPD
Read More
Bayer Healthcare divulges TNKS1/TNKS2 inhibitors for cancer
Read More